Immune System Key Ltd.
  • Home
  • News & Events
  • Science And R&D
    • Nerofe Pipeline
    • Technology
    • Phase I Results
    • First Success Story
  • Company Description
    • Team
  • Contact Us
Immune System Key Ltd.
  • Home
  • News & Events
  • Science And R&D
    • Nerofe Pipeline
    • Technology
    • Phase I Results
    • First Success Story
  • Company Description
    • Team
  • Contact Us

ISK received the FDA’s approval to start Phase 1b/2a with AML patients

  • Home
  • News
  • ISK received the FDA’s approval to start Phase 1b/2a with AML patients

ISK received the FDA’s approval to start Phase 1b/2a with AML patients

January 9, 2020
Joel Ohana2020-01-15T14:27:25+00:0009 Jan|

Related Posts

  • Cooperation with Harvard Medical School (MGH)

    October 27, 2019

    ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases

  • Prof. Marc E. Lippman – Famous breast cancer expert (KOL ) has joined ISK Ltd

    April 9, 2019

    Marc E. Lippman, MD, MACP FRCP is the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard School of Medicine, and was Chairman of the Department of Medicine from May 2007 to May 2012. He is currently Deputy Director of the Sylvester Comprehensive Cancer Center. Previously Dr. Lippman was the John […]

  • ISK attended the 2019 Sachs conference in Zurich

    March 5, 2019
  • Prof. Rosenblatt, Joseph D, M.D, a KOL in hematology, has joined ISK’s advisory board

    February 25, 2019
  • Nerofe has received a new US patent for metastatic cancer treatment

    November 21, 2018
  • Permalink Gallery

    Cooperation with Harvard Medical School (MGH)

  • Permalink Gallery

    Prof. Marc E. Lippman – Famous breast cancer expert (KOL ) has joined ISK Ltd

  • ISK at Sachs conference
    Permalink Gallery

    ISK attended the 2019 Sachs conference in Zurich

  • Rosenblatt, Joseph D, M.D
    Permalink Gallery

    Prof. Rosenblatt, Joseph D, M.D, a KOL in hematology, has joined ISK’s advisory board

  • Permalink Gallery

    Nerofe has received a new US patent for metastatic cancer treatment

Recent Posts

  • ISK received the FDA’s approval to start Phase 1b/2a with AML patients
  • Cooperation with Harvard Medical School (MGH)
  • Prof. Marc E. Lippman – Famous breast cancer expert (KOL ) has joined ISK Ltd
  • ISK attended the 2019 Sachs conference in Zurich
  • Prof. Rosenblatt, Joseph D, M.D, a KOL in hematology, has joined ISK’s advisory board

Tags

article cancer Clinical Trial drug therapy ISK dtcapfs human trial Immune System Key immunotherapy ISK Nerofe Phase I SACH tumor Zurich

Categories

  • News
  • About
  • News & Events
  • Contact Us
  • Disclaimer
Immune System Key (ISK) Ltd. Hava'ad Haleumi 21, Jerusalem 91160, Israel Tel: +972-50-2597031/2
logo
Copyright © 2015 ISK Ltd.